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There is an outbreak of Neisseria gonorrhoeae with high-level resistance to azithromycin in 
England.1 Since publication of this news article in the BMJ in April 2016,2 an additional 22 
cases have been identified, with a total of 56 confirmed cases by October 2016.3  
Most gonorrhoea diagnoses in England are made in specialist sexual health clinics (SHCs), 
but around 5% are made in general practice (GP).4 The national treatment guideline 
recommends dual therapy of 500mg ceftriaxone (intramuscularly) and 1g azithromycin 
(orally) as first-line, to help extend the useful life of cephalosporins. 5 While over 90% of 
cases treated at SHCs receive the recommended first-line therapy, 3, 5 only 9% of cases 
treated by GPs between 2011 and 2014 did so. 4  
The national guideline allows for azithromycin monotherapy as an alternative regimen where 
it is difficult to provide an intramuscular injection (for ceftriaxone); 5 from 2011 to 2014, 19% 
of cases treated by GPs received azithromycin monotherapy, but at 1g, rather than the 
recommended 2g dose.  
In the context of increasing resistance to azithromycin, the use of azithromycin monotherapy 
to treat gonorrhoea, especially with a suboptimal dosage, increases both the likelihood of 
treatment failure and the selection pressure for the development of ceftriaxone resistance.  
GPs are encouraged to refer cases of gonorrhoea to SHCs but should treat patients deemed 
likely to be lost to follow-up. 6 However, to limit the spread of antimicrobial resistance and 
ensure gonorrhoea remains a treatable infection, use of first-line therapy in all settings is 
strongly recommended. 
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